title: Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness.
abstract: OBJECTIVE
  To study the effect of medroxyprogesterone on blood gases and cerebral regional oxygenation at high altitude, alone and in conjunction with acetazolamide, and to assess the effect on acute mountain sickness (AMS).
  
  
  METHODS
  Two placebo-controlled trials during rapid ascent to high altitude.
  
  
  METHODS
  In the first trial, 20 participants, and in the second trial, 24 participants.
  
  
  METHODS
  During rapid ascent to 4680 m and on rapid ascent to 5200 m.
  
  
  METHODS
  In the first trial, participants were randomized to receive medroxyprogesterone 30 mg or a placebo twice a day. In the second trial, participants were randomly assigned to one of 4 groups: a placebo twice daily, medroxyprogesterone 30 mg twice daily, acetazolamide 250 mg plus a placebo twice daily, or acetazolamide 250 mg plus medroxyprogesterone 30 mg twice daily.
  
  
  METHODS
  Blood gas changes and symptom scores of AMS in both trials and cerebral regional oxygen saturations in the first trial only.
  
  
  RESULTS
  Medroxyprogesterone improved peripheral oxygen saturations in both trials and improved PaO2 in combination with acetazolamide. Cerebral regional oxygen saturation was not altered by medroxyprogesterone. The reduction in symptom scores and in the extent of AMS was not significant in this limited study.
  
  
  CONCLUSIONS
  Medroxyprogesterone acts as a respiratory stimulant, but the clinical benefit regarding the development of AMS was unproven at high altitude. Combined medroxyprogesterone and acetazolamide gave the best PaO2.
authors.affiliation: Department of Medicine, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
authors.forename: Alex D
authors.initials: AD
authors.lastname: Wright
authors.forename: Margaret F
authors.initials: MF
authors.lastname: Beazley
authors.forename: Arthur R
authors.initials: AR
authors.lastname: Bradwell
authors.forename: Ian M
authors.initials: IM
authors.lastname: Chesner
authors.forename: Richard N
authors.initials: RN
authors.lastname: Clayton
authors.forename: Peter J G
authors.initials: PJ
authors.lastname: Forster
authors.forename: Peter
authors.initials: P
authors.lastname: Hillenbrand
authors.forename: Christopher H E
authors.initials: CH
authors.lastname: Imray
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000531:Altitude; D000532:Altitude Sickness / Q000097:blood / Q000517:prevention & control*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D001784:Blood Gas Analysis; D001921:Brain / Q000378:metabolism*; D002245:Carbon Dioxide / Q000097:blood*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010100:Oxygen / Q000097:blood / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002245:Carbon Dioxide; D008525:Medroxyprogesterone; D000086:Acetazolamide; D010100:Oxygen